Literature DB >> 14508390

A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume.

Michael E Chen1, Dennis Johnston, Adriana O Reyes, Cindy P Soto, R Joseph Babaian, Patricia Troncoso.   

Abstract

Prostate tumor volume has been suggested to be an important pathologic variable that predicts for clinical significance and outcome. However, the determination of tumor volume using standard methods such as computerized planimetry or image analysis is labor intensive. We studied whether length (L), width (W), and height (number of cross sections x sectional thickness, CST) of a tumor focus could be used to estimate prostate tumor volume. We studied 1091 tumor foci from 365 selected serially sectioned radical prostatectomy specimens. We randomly divided the specimens into evaluation (182 specimens) and validation (183 specimens) groups. After analyzing the evaluation group, we derived the formula 0.4 (slope of the regression line) x L x W x CST to estimate volume. We then tested whether our three-dimensional volume estimation formula could accurately classify tumor volume for specimens in the validation set as insignificant (</=0.5 cm3) or significant (>0.5 cm3), and also into a five-category tumor volume scheme. Our three-dimensional estimate accurately classified tumors into insignificant and significant total volume categories in 94.0% of cases and into the five-category scheme in 85.8% cases. These accuracy rates were significantly better than rates for other methods. The three-dimensional estimate is an accurate and straightforward method for assessing prostate tumor volume.

Entities:  

Mesh:

Year:  2003        PMID: 14508390     DOI: 10.1097/00000478-200310000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

1.  Neoadjuvant Enzalutamide Prior to Prostatectomy.

Authors:  Bruce Montgomery; Maria S Tretiakova; Anthony M Joshua; Martin E Gleave; Neil Fleshner; Glenn J Bubley; Elahe A Mostaghel; Kim N Chi; Daniel W Lin; Martin Sanda; William Novotny; Kenneth Wu; Philip W Kantoff; Brett T Marck; Stephen Plymate; Steven P Balk; Peter S Nelson; Alvin M Matsumoto; Rosina T Lis; Adam Kibel; Gabriel P Haas; Andrew Krivoshik; Alison Hannah; Mary-Ellen Taplin
Journal:  Clin Cancer Res       Date:  2016-11-09       Impact factor: 12.531

2.  A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer.

Authors:  Claire Murphy; Lawrence True; Funda Vakar-Lopez; Jing Xia; Roman Gulati; Bruce Montgomery; Maria Tretiakova
Journal:  Prostate       Date:  2016-06-08       Impact factor: 4.104

3.  Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Authors:  Mary-Ellen Taplin; Bruce Montgomery; Christopher J Logothetis; Glenn J Bubley; Jerome P Richie; Bruce L Dalkin; Martin G Sanda; John W Davis; Massimo Loda; Lawrence D True; Patricia Troncoso; Huihui Ye; Rosina T Lis; Brett T Marck; Alvin M Matsumoto; Steven P Balk; Elahe A Mostaghel; Trevor M Penning; Peter S Nelson; Wanling Xie; Zhenyang Jiang; Christopher M Haqq; Daniel Tamae; NamPhuong Tran; Weimin Peng; Thian Kheoh; Arturo Molina; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2014-10-13       Impact factor: 44.544

4.  Total intraglandular and index tumor volumes predict biochemical recurrence in prostate cancer.

Authors:  Su-Jin Shin; Cheol Keun Park; Sung Yoon Park; Won Sik Jang; Joo Yong Lee; Young Deuk Choi; Nam Hoon Cho
Journal:  Virchows Arch       Date:  2016-06-15       Impact factor: 4.064

5.  In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence.

Authors:  Yujiro Ito; Emily A Vertosick; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; Sahussapont J Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

6.  Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

Authors:  Vassiliki Tzelepi; Eleni Efstathiou; Sijin Wen; Patricia Troncoso; Maria Karlou; Curtis A Pettaway; Louis L Pisters; Anh Hoang; Christopher J Logothetis; Lance C Pagliaro
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

7.  Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue volume in patients undergoing radical prostatectomy: a new predictor of biochemical recurrence in localized or locally advanced prostate cancer.

Authors:  Ja Hyeon Ku; Kyung Chul Moon; Sung Yong Cho; Cheol Kwak; Hyeon Hoe Kim
Journal:  Asian J Androl       Date:  2010-11-22       Impact factor: 3.285

8.  Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci.

Authors:  John W Davis; Jeri Kim; John F Ward; Xuemai Wang; Hiro Nakanishi; R Joseph Babaian; Patricia Troncoso
Journal:  BJU Int       Date:  2009-11-03       Impact factor: 5.588

9.  Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification.

Authors:  Eleni Efstathiou; Neil A Abrahams; Rita F Tibbs; Xuemei Wang; Curtis A Pettaway; Louis L Pisters; Paul F Mathew; Kim-Anh Do; Christopher J Logothetis; Patricia Troncoso
Journal:  Eur Urol       Date:  2009-10-17       Impact factor: 20.096

10.  Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.

Authors:  Dimitra Tsavachidou; Timothy J McDonnell; Sijin Wen; Xuemei Wang; Funda Vakar-Lopez; Louis L Pisters; Curtis A Pettaway; Christopher G Wood; Kim-Anh Do; Peter F Thall; Clifton Stephens; Eleni Efstathiou; Robert Taylor; David G Menter; Patricia Troncoso; Scott M Lippman; Christopher J Logothetis; Jeri Kim
Journal:  J Natl Cancer Inst       Date:  2009-02-24       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.